Point-of-care assay demonstrates 100% sensitivity for sickle cell disease in 166 individuals, indicating scalable testing may improve access to diagnostics.
Key Points
The assay achieved 100% sensitivity and 97% specificity in diagnosing sickle cell disease.
Using hemoglobin chromatography as a gold standard, the test distinguishes among hemoglobin phenotypes.
This point-of-care assay utilizes a simple procedure with whole blood and smartphone analysis for diagnostics.
The findings suggest significant potential for expanding sickle cell disease screening in low-resource healthcare systems.